EDGAR Filing Documents for 0001564590-14-005661

Form 8-K - Current report:

SEC Accession No. 0001564590-14-005661

Filing Date

2014-11-13

Accepted

2014-11-13 16:36:54

Documents

Period of Report

2014-11-06

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	ctic-8k_20141113.htm	8-K	79646
2	EX-1.1	ctic-ex11_201411136.htm	EX-1	246958
3	EX-3.1	ctic-ex31_20141113711.htm	EX-3	105258
4	EX-5.1	ctic-ex51_20141113462.htm	EX-5	16526
5	EX-99.1	ctic-ex991_201411137.htm	EX-99	13428
6	EX-99.2	ctic-ex992_20141113174.htm	EX-99	14545
7	GRAPHIC	g20141113202853596231.jpg	GRAPHIC	7881
8	GRAPHIC	g20141113202858328177.jpg	GRAPHIC	7883
	Complete submission text file	0001564590-14-005661.txt		499840

Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121

Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100

CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)